Literature DB >> 8507124

Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology.

D A Redelmeier1, K Lorig.   

Abstract

OBJECTIVE: To estimate when a difference in disability symptoms is sufficiently large to be important to individual patients.
DESIGN: Cross-sectional analysis of two groups: derivation set (n = 46) and validation set (n = 57).
SETTING: The Arthritis Foundation, Northern California Chapters. PARTICIPANTS: Volunteer sample of patients with arthritis who live in the community. MAIN OUTCOME MEASURES: We applied the Stanford Health Assessment Questionnaire to assess the functional status of individuals. Participants then conducted one-on-one conversations with each other and rated whether their disability was "much better" "somewhat better," "about the same," "somewhat worse," or "much worse" relative to each person they met. For every conversation we calculated the difference between the two participants' health assessment questionnaire scores and linked the difference to the subjective comparison ratings of each individual in the pair.
RESULTS: Health assessment questionnaire score differences were significantly correlated with subjective comparison ratings (correlation coefficient, .41; 95% confidence interval, 0.31 to 0.50). We estimated that health assessment questionnaire scores needed to differ by about 0.19 units for average respondents to stop rating themselves as "about the same" and start rating themselves as "somewhat better" (95% confidence interval, 0.10 to 0.28). Analysis of a second group of patients revealed a similar threshold (mean, 0.23 units; 95% confidence interval, 0.13 to 0.23). In both groups, health assessment questionnaire score differences were imperfect predictors of individual ratings and the threshold for less disabled participants tended to be lower than the threshold for more disabled participants.
CONCLUSIONS: Some statistically significant differences in functional status scores may be so small that they represent trivial degrees of symptom relief. An awareness of the smallest difference in symptom scores that is important to patients can provide a rough guide to help clinicians interpret the medical literature.

Entities:  

Mesh:

Year:  1993        PMID: 8507124

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  44 in total

Review 1.  Determination of the clinical importance of study results.

Authors:  Malcolm Man-Son-Hing; Andreas Laupacis; Keith O'Rourke; Frank J Molnar; Jeffery Mahon; Karen B Y Chan; George Wells
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

2.  Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.

Authors:  Srinivas Raman; Keyue Ding; Edward Chow; Ralph M Meyer; Yvette M van der Linden; Daniel Roos; William F Hartsell; Peter Hoskin; Jackson S Y Wu; Abdenour Nabid; Rick Haas; Ruud Wiggenraad; Scott Babington; William F Demas; Carolyn F Wilson; Rebecca K S Wong; Liting Zhu; Michael Brundage
Journal:  Qual Life Res       Date:  2017-11-29       Impact factor: 4.147

3.  Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?

Authors:  Carlo A Marra; Amir A Rashidi; Daphne Guh; Jacek A Kopec; Michal Abrahamowicz; John M Esdaile; John E Brazier; Paul R Fortin; Aslam H Anis
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

4.  Values for function in rheumatoid arthritis: patients, professionals, and public.

Authors:  S Hewlett; A P Smith; J R Kirwan
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

5.  Clinically important change in quality of life in epilepsy.

Authors:  S Wiebe; S Matijevic; M Eliasziw; P A Derry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

6.  Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis.

Authors:  Jacques Pouchot; Raheem B Kherani; Rollin Brant; Diane Lacaille; Allen J Lehman; Stephanie Ensworth; Jacek Kopec; John M Esdaile; Matthew H Liang
Journal:  J Clin Epidemiol       Date:  2008-03-21       Impact factor: 6.437

7.  Coping with prescription medication costs: a cross-sectional look at strategies used and associations with the physical and psychosocial health of individuals with arthritis.

Authors:  Kathryn Remmes Martin; Jack Shreffler; Britta Schoster; Leigh F Callahan
Journal:  Ann Behav Med       Date:  2012-10

8.  Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.

Authors:  F Wolfe; K Michaud; E M Dewitt
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).

Authors:  Jane T Osterhaus; Oana Purcaru; Lance Richard
Journal:  Arthritis Res Ther       Date:  2009-05-20       Impact factor: 5.156

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.